Everything announced at the Nintendo Direct: Partner Showcase July 2025
That would be a totally healthy response, but be warned: The fakers are coming. Take everything you see and hear this weekend with some healthy skepticism until the dust clears.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Turns out it wasn't a scheduling conflict.
Bill Hader has revealed that his absence at the Saturday Night Live 50th anniversary special was not due to a scheduling conflict, as claimed by his publicist at the time, but because of his long-running struggles with anxiety. 'Andy [Samberg] called me and was like, 'Hey, so we're doing this short about how, you know, everybody had anxiety...'' Hader recalled. 'And when he told me that, I was like, 'I don't know if I want to do that.'' Hader continued, 'He's like, 'Why?' And I'm like, 'Because I'm anxious. I don't want to do it.''
Yahoo
22 minutes ago
- Yahoo
Intel Rallies Despite Fitch Downgrade
Intel (NASDAQ:INTC) got a surprise downgrade from Fitch this week, yet its stock popped about 3.6% anyway. The agency dialed down Intel's long-term credit rating from BBB+ to BBB, pointing to a tougher demand backdrop and the need for debt reduction and stronger product ramps over the next year or two. Short-term ratings stayed at F2, so it's not all doom and gloom. Warning! GuruFocus has detected 6 Warning Signs with INTC. At the same time, Intel's next-gen 18A process is acting up. Early reports suggest Panther Lake chips have roughly three times the defect rate they should, and volume ramps are lagging. That's a headache so close to the planned Q4 launch, especially when smooth ramp-up was supposed to prove we're past the worst of manufacturing woes. Still, investors seem to be looking past the short-term noise. Maybe a rebound in PC and data-center spendingor a clean bill of health at the August 12 bond covenant updatewill do the trick. The real verdict, though, will come with Q3 production progress and any signs that Panther Lake irons out its kinks. This article first appeared on GuruFocus.
Yahoo
22 minutes ago
- Yahoo
Recursion Sets $100 Million Partnership Goal by 202
Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher Gibson talked up how the Exscientia tech and the Boltz-2 partnership with MIT and Nvidia have supercharged their end-to-end platformfrom pinpointing targets to simulating trials. That boost in efficiency shines through in their finances. Warning! GuruFocus has detected 6 Warning Signs with RXRX. CFO Ben Taylor confirmed they finished Q2 with $533 M in the bank and expect to keep burn under $390 M next year. Even better, they're targeting over $100 M in partnership inflows by the end of 2026, which should carry them all the way through Q4 2027 without needing extra financing. On the science side, six internal programs are nearing key milestones. Oncology dose-escalation data should roll in by year-end and rare-disease updates are due early next year. The ClinTech AI platform now promises roughly 50 % faster enrollment projections, and they've hit a fourth Sanofi milestone while rolling out neuronal phenomaps with Roche and Genentech. This article first appeared on GuruFocus.
